A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Latest Information Update: 23 Feb 2026
At a glance
- Drugs GK 01 Beijing Geekgene Technology (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms GIMINI
- Sponsors Beijing Geekgene Technology
Most Recent Events
- 23 Feb 2026 New trial record